Skip to main content

Addex Therapeutics Ltd. (ADXN)

NASDAQ: ADXN · IEX Real-Time Price · USD
7.12
-0.20 (-2.67%)
At close: Nov 26, 2021 1:00 PM
7.00
-0.12 (-1.69%)
After-hours:Nov 26, 2021 1:00 PM EST
Market Cap41.88M
Revenue (ttm)4.72M
Net Income (ttm)-14.19M
Shares Out5.88M
EPS (ttm)-2.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume640
Open7.67
Previous Close7.32
Day's Range7.00 - 7.12
52-Week Range7.50 - 35.00
Beta1.41
Analystsn/a
Price Targetn/a
Earnings DateNov 4, 2021

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col...

IndustryBiotechnology
Founded2002
CEOTim Dyer
Employees27
Stock ExchangeNASDAQ
Ticker SymbolADXN
Full Company Profile

Financial Performance

In 2020, ADXN's revenue was 3.61 million, an increase of 30.77% compared to the previous year's 2.76 million. Losses were -12.86 million, -13.00% less than in 2019.

Financial numbers in millions CHFFinancial Statements

News

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0.00% and 96.43%, respectively, for the quarter ended September 2021.

3 weeks ago - Zacks Investment Research

Addex Therapeutics Ltd. Sponsored ADR (ADXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Addex Therapeutics Ltd. Sponsored ADR (ADXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 month ago - Zacks Investment Research

Addex Therapeutics, CMTA Join Forces To Develop Potential Treatment For Rare Neurological Disorder

The Charcot–Marie–Tooth Association (CMTA), a philanthropic funder of CMT research worldwide, and Addex Therapeutics Ltd (NASDAQ: ADXN) have collaborated to investigate a potential therapy for CMT type ...

2 months ago - Benzinga

New Strong Sell Stocks for August 20th

ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.

Other symbols:CSSEHSDTLYRATRVN
3 months ago - Zacks Investment Research

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Tops Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -18.46% and 352.31%, respectively, for the quarter ended June 2021.

3 months ago - Zacks Investment Research

Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?

Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.

4 months ago - Zacks Investment Research

Addex Reports Q1 2021 Financial Results and Provides Corporate Update

Ge neva, Switzerland, May 5 , 20 2 1 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, tod...

6 months ago - GlobeNewsWire

Enamine Extend Collaboration With Prominent Swiss Biotech

KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world's largest collections of building blocks, fragments and screening compounds announced today th...

9 months ago - Business Wire

Why Addex, Genetic Technologies And Obalon Are Moving Today

Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone...

Other symbols:GENE
10 months ago - Benzinga

Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is Soaring Today

Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is...

10 months ago - InvestorPlace

Addex Announces Pricing of $10.0 Million Global Offering

Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...

10 months ago - GlobeNewsWire